SGLT2 Inhibitor Promotes Ketogenesis to Improve MASH by Suppressing CD8+ T Cell Activation

SGLT2 Inhibitor Promotes Ketogenesis to Improve MASH by Suppressing CD8+ T Cell Activation

Research on SGLT2 Inhibitors Alleviating MASH by Enhancing Ketogenesis to Inhibit CD8+ T Cell Activation Research Background and Problem Positioning Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become a global health concern. Its severe stage, Metabolic Dysfunction-Associated Steatohepatitis (MASH), leads to hepatocyte damag...